NEOnatal Central-venous Line Observational study on Thrombosis (NEOCLOT): evaluation of a national guideline on management of neonatal catheter-related thrombosis
Authors:
- Jeanine J. SolJSJeanine J. Sol
- Moniek van de LooMLMoniek van de Loo
- Marit BoermaMBMarit Boerma
- Klasien A. BergmanKBKlasien A. Bergman
- Albertine E. DonkerADAlbertine E. Donker
- Mark A. H. B. M. van der HoevenMHMark A. H. B. M. van der Hoeven
- Christiaan V. HulzebosCHChristiaan V. Hulzebos
- Ronny KnolRKRonny Knol
- K. Djien LiemKLK. Djien Liem
- Richard A. van LingenRLRichard A. van Lingen
- Enrico LoprioreEnrico Lopriore
- Monique H. SuijkerMSMonique H. Suijker
Open Access
- 23 February 2018
- journal article
- research article
- Published by Springer Nature in BMC Pediatrics
- Vol. 18 (1) , 1-8
Abstract
In critically ill (preterm) neonates, central venous catheters (CVCs) are increasingly used for administration of medication or parenteral nutrition. A serious complication, however, is the development of catheter-related thrombosis (CVC-thrombosis), which may resolve by itself or cause severe complications. Due to lack of evidence, management of neonatal CVC-thrombosis varies among neonatal intensive care units (NICUs). In the Netherlands an expert-based national management guideline has been developed which is implemented in all 10 NICUs in 2014. The NEOCLOT study is a multicentre prospective observational cohort study, including 150 preterm and term infants (0-6 months) admitted to one of the 10 NICUs, developing CVC-thrombosis. Patient characteristics, thrombosis characteristics, risk factors, treatment strategies and outcome measures will be collected in a web-based database. Management of CVC-thrombosis will be performed as recommended in the protocol. Violations of the protocol will be noted. Primary outcome measures are a composite efficacy outcome consisting of death due to CVC-thrombosis and recurrent thrombosis, and a safety outcome consisting of the incidence of major bleedings during therapy. Secondary outcomes include individual components of primary efficacy outcome, clinically relevant non-major and minor bleedings and the frequency of risk factors, protocol variations, residual thrombosis and post thrombotic syndrome. The NEOCLOT study will evaluate the efficacy and safety of the new, national, neonatal CVC-thrombosis guideline. Furthermore, risk factors as well as long-term consequences of CVC-thrombosis will be analysed. Trial registration: Nederlands Trial Register NTR4336 . Registered 24 December 2013.Keywords
Funding Information
- Daiichi Sankyo Company (Unrestricted grant)
This publication has 29 references indexed in Scilit:
- Antithrombotic Therapy in Neonates and ChildrenChest, 2012
- Parenteral AnticoagulantsChest, 2012
- Management and Outcome in 32 Neonates with Thrombotic EventsInternational Journal of Pediatrics, 2011
- Neonatal and childhood right atrial thrombosis: recognition and a risk-stratified treatment approachBlood Coagulation & Fibrinolysis, 2010
- Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit?Cardiology in the Young, 2010
- Evaluation of enoxaparin dosing requirements in infants and childrenThrombosis and Haemostasis, 2009
- The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5‐year overviewJournal of Thrombosis and Haemostasis, 2007
- Paradoxical embolism in a preterm infantDevelopmental Medicine & Child Neurology, 2004
- Paradoxical embolism in a preterm infantDevelopmental Medicine & Child Neurology, 2004
- Successful Use of Tissue Plasminogen Activator in Catheter-Related Intracardiac Thrombus of a Premature InfantAmerican Journal of Perinatology, 2003